Table 1 Demographic, transplant, and ADV disease characteristics of patients.
Characteristics | N (%) |
|---|---|
N | 30 |
Gender (M/F) | 22/8 (73/27) |
Median age (years) | 10 (range: 9 months–19 years) |
Disease | |
ALL | 13 (43) |
AML | 6 (20) |
NHL | 2 (7) |
MDS | 1 (3) |
CML | 1 (3) |
ID | 3 (10) |
Fanconi’s anemia | 2 (7) |
ADLD | 1 (3) |
JMML | 1 (3) |
Disease status | |
I CR | 12 (40) |
≥II CR | 11 (37) |
Refractory/relapse | 2 (7) |
NNHD | 5 (17) |
Donor type | |
Haploidentical | 16 (53) |
Identical sibling | 1 (3) |
MUD | 11 (37) |
Cord blood | 2 (7) |
2nd HSCT | 11 (37) |
Acute GvHD | 15/30 (50) |
Grade I–II | 6 (20) |
Grade III | 5 (17) |
Grade IV | 4 (13) |
Chronic GvHD | |
Limited | 1/30 (3) |
Extensive | 0 |
CSA | |
Yes/no | 18/12 |
Antiviral prophylaxis | |
Aciclovir | 23 (77) |
Ganciclovir | 2 (7) |
Valganciclovir | 1 (3) |
Valaciclovir | 2 (7) |
Foscarnet | 1 (3) |
ADV reactivation | 30/30 (100) |
ADV disease | 26/30; 44 episodes |
GI tract | 18/44 (41) |
Kidney/Bladder | 6/44 (14) |
Upper resp. tract | 3/44 (7) |
Pneumonia | 4/44 (9) |
Liver | 5 /44 (11) |
Disseminated dis. | 6/30 (20) |
Time from HSCT (median) range | 3 months (20 days–14 months) |
First-line therapy | |
CDV | 23/30 (77) |
BCV | 7/30 (23) |
Rescue therapy | |
BCV (yes/no) | 14/9 |
Toxicity | |
CDV (grade) | 4 (2:1–2; 1:2; 1:3) |
BCV (grade) | 1 (2) |
Treatment duration | |
CDV (median, range) | 4 weeks (1–12) |
BCV (median, range) | 2 weeks (4 days–12 weeks) |
Response to CDV | |
CR | 8/23 (35) |
PR | 1/23 (4) |
SD | 2/23 (8) |
PD | 12/23 (52) |
Response to BCV | |
CR | 10/21 (48) |
PR | 2/21 (9,5) |
SD | 2/21 (9,5) |
PD | 5/21 (24) |
Outcome | |
Dead | 20 (67) |
Alive | 10 (33) |
Cause of death | |
Relapse/progression | 10 (33) |
ADV infection | 4 (13) |
Other TRM | 6 (20) |
Follow-up | |
Median | 12 months |
Range | (2–43) |
